home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

252.86 -5.52 (-2.14%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

3 Cannabis Stocks With Double-Digit Percentage Revenue Growth ↗

January 30, 2023

Their shares may be down, but their sales are up.

Via The Motley Fool

The Ultimate Growth Stocks to Buy With $300 Right Now ↗

January 29, 2023

These three companies should deliver inflation-busting long-term growth.

Via The Motley Fool

2 Promising New Growth Stocks to Watch in 2023 ↗

January 23, 2023

These stocks have plenty of room to run.

Via The Motley Fool

Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer ↗

January 19, 2023

Via Benzinga

2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher ↗

January 11, 2023

There are still plenty of growth opportunities left for these businesses.

Via The Motley Fool

These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy. ↗

January 07, 2023

These stocks look cheap if you take a long-term view.

Via The Motley Fool

Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart? ↗

January 06, 2023

Via Benzinga

2 Cannabis Stocks to Buy for the Long Haul ↗

December 31, 2022

Don't give up on this sector too quickly.

Via The Motley Fool

Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks ↗

December 21, 2022

Via Benzinga

Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court ↗

January 05, 2023

Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS

Via Benzinga

2 Growth Stocks to Buy Heading Into 2023 ↗

December 30, 2022

These biotechs are far from having achieved their full potential.

Via The Motley Fool

2 Top Biotech Stocks to Buy for the Long Haul ↗

December 25, 2022

These mid-cap biotechs are solid long-term choices.

Via The Motley Fool

Better Buy: Moderna vs Axsome ↗

December 22, 2022

Revenue prospects look promising for both of these biotech companies.

Via The Motley Fool

Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today ↗

December 21, 2022

U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation...

Via Benzinga

6 Analysts Have This to Say About Jazz Pharmaceuticals ↗

December 09, 2022

Via Benzinga

What 6 Analyst Ratings Have To Say About Jazz Pharmaceuticals ↗

December 09, 2022

Via Benzinga

After Jumping 100%, Is Axsome a Buy Before 2023? ↗

December 16, 2022

Axsome's revenue story is just getting started.

Via The Motley Fool

Netflix To Rally Around 29%? Here Are 10 Other Price Target Changes For Friday ↗

December 09, 2022

Wells Fargo raised Netflix, Inc. (NASDAQ: NFLX) price target from $300 to $400. Wells Fargo also upgraded the stock from Equal Weight to Overweight. Netflix shares rose 0.6% to close at $310.26 on...

Via Benzinga

2 Unstoppable Growth Stocks to Buy in 2022 and Beyond ↗

December 08, 2022

These biotech players beat the bear market this year.

Via The Motley Fool

3 Fierce Stocks That Are Screaming Buys in December ↗

December 07, 2022

Here are three winners in the making.

Via The Motley Fool

Jazz Caregiver Survey: CBD-Based Epidiolex Improves Seizure & Non-Seizure Outcomes In Patients With Severe Epilepsy ↗

December 05, 2022

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) caregiver survey that showed a substantial proportion of caregivers...

Via Benzinga

Biotech Space Offers Reward In 2023 Despite Economic Risks ↗

November 30, 2022

Despite the economic headwinds, the mid-to long-term outlook for the biotech space remains strong, and investors who are able to take advantage of undervalued biotech stocks may be well-positioned for...

Via Talk Markets

Struggling Axsome Stock Could Bounce Back on Drug Trial Success

November 30, 2022

Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that.

Via MarketBeat

Q3 Proves To Be Another Tough Quarter For Cannabis ↗

November 28, 2022

It’s been a tough year for cannabis investors and Q3 offered little relief.

Via Talk Markets

Goldman Sachs, Walmart And These 2 Stocks Insiders Are Selling ↗

November 28, 2022

The Nasdaq Composite dropped around 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Want to Double Your Money? Buying These Stocks Could be a Genius Move ↗

November 28, 2022

These stocks are undervalued considering their long-term growth potential.

Via The Motley Fool

Prediction: This Growth Stock Could Double in 2023 ↗

November 24, 2022

The next year should be a busy one for this drugmaker.

Via The Motley Fool

Three CBD Stocks to Dominate a Budding Industry

November 23, 2022

The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity.

Via MarketBeat

Topics Cannabis

Analyst Bumps Up Price Target For Avadel Pharmaceuticals After Favorable Patent Ruling ↗

November 21, 2022

Last Friday, Delaware District Court granted Avadel Pharmaceuticals plc's (NASDAQ: AVDL) motion to delist the ‘963 Xyrem REMS patent.

Via Benzinga

Avadel Pharmaceuticals Announces Favorable Ruling Regarding Sleep Disorder Drug Patent ↗

November 21, 2022

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com